Viewing records where tag name contains "investor" View All

US patent granted for DEP Bcl2/xL inhibitor conjugates

Jun 12th, 2019

Starpharma announced the first patent for DEP® Bcl2/xL inhibitor conjugates, developed in collaboration with AstraZeneca, has been granted by the US Patent and Trademark Office. These patented DEP® Bcl2/xL inhibitor conjugates combine Starpharma’s innovative DEP® delivery technology with AstraZeneca’s novel Bcl2/xL inhibitors, which are being investigated for treating various cancers, including leukemias.

 

Read More

Okamoto launches VivaGel® condom in Japan

Jun 4th, 2019

Starpharma today announced that the VivaGel® condom has been launched in Japan under Okamoto’s leading and highly successful Zero Zero Three (003) brand. This is the first condom with antiviral coating in Japan and will also carry Starpharma’s VivaGel® brand.

Read More

Starpharma signs second oncology agreement with AstraZeneca

Jun 3rd, 2019

Starpharma today announced a Development and Option Agreement with AstraZeneca (LON: AZN) to progress the development of a Dendrimer Enhanced Product (DEP®) version of an undisclosed AstraZeneca major marketed oncology medicine. This is the second DEP® commercial agreement Starpharma has signed with AstraZeneca, the first agreement being a multiproduct licence which covers novel oncology drug candidates such as AZD0466 (a Bcl2/xL inhibitor).

Read More

Starpharma presents at UBS Healthcare Conference

May 29th, 2019

Starpharma has been invited to present today at the UBS Australian Emerging Companies Conference - Healthcare and Biotech – in Sydney. The UBS Healthcare Conference provides Starpharma with an opportunity to present to approximately 100 institutional investors.

Read More

DEP® irinotecan combination outperforms in refractory human colon cancer model

May 24th, 2019

Starpharma today announced that its patented nanoparticle formulation, DEP® irinotecan, showed significant efficacy and safety benefits over leading colorectal cancer drugs irinotecan (Camptosar®) and cetuximab (Erbitux®), in the irinotecan-refractory HT-29 human colon cancer model.

These impressive results were despite the fact that these standard colorectal cancer (CRC) treatments, Camptosar® and/or Erbitux®, showed limited activity in this preclinical model.

Read More

Regulatory progress for VivaGel BV in the US

May 23rd, 2019

Starpharma has received formal feedback from the recent meeting held with the US FDA in relation to the approval for two related bacterial vaginosis (BV) indications - BV treatment and the prevention of recurrent BV in the United States.

Read More

Starpharma to present at US Drug Delivery Conference

May 7th, 2019

Starpharma today announced that it will be presenting its DEP® platform at the 2nd Annual Drug Delivery West conference in San Francisco on 6-7 May 2019 (US time).

 

Read More

Starpharma presents at Macquarie Australia Conference

May 1st, 2019

Melbourne, Australia; 1 May 2019: Starpharma (ASX: SPL, OTCQX: SPHRY) has been invited to present today at the Macquarie Australia Conference in Sydney. The Macquarie Australia Conference is a leading investment event in Australia and attracts more than 800 investors from around the world, including Asia, Europe and North America.

 

Read More

Quarterly Cashflow Report

Apr 29th, 2019

Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 March 2019.

 

Read More

First VivaGel BV launch globally in Australia by Aspen

Apr 16th, 2019

Starpharma today announced that VivaGel® BV has been officially launched in Australia by Aspen Pharmacare (Aspen) as Fleurstat BVgel. The product has undergone distribution across Australia and is already available in some pharmacies. It will be progressively rolled-out nationally over the coming weeks. This is the first launch of VivaGel® BV in the world and further launches by Mundipharma are expected in Europe in May/June this year.

Read More

Starpharma meets with US FDA to discuss VivaGel® BV

Apr 11th, 2019

 

Starpharma today announced that a meeting was held with the US FDA overnight as part of the process to clarify and address FDA’s request for confirmatory data prior to the approval of VivaGel® BV in the US. This meeting was attended by senior representatives of Starpharma as well as internationally recognised Key Opinion Leaders in BV, statisticians and the Company’s expert FDA regulatory consultants, which include former senior FDA clinical personnel. 

Read More

Starpharma Investor Presentation to Goldman Sachs Conference

Apr 3rd, 2019

Starpharma will today present to institutional investors at the Goldman Sachs Tenth Annual Emerging Companies Conference in Sydney.

 

Read More

Shareholder Update March 2019

Mar 18th, 2019

In this issue: 

>> Fleurstat BVgel - Australian launch

>> Mundipharma's European launch of VivaGel® BV

>> Mundipharma's international roll-out of VivaGel® BV

>> FDA meeting to discuss VivaGel® BV approval in the US

 Download: Shareholder Update March 2019 (pdf file, 453kb)

Read More

Starpharma receives $4.0M R&D tax incentive refund

Mar 12th, 2019

Melbourne, Australia: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that it has received a $4.0M R&D tax incentive refund which relates to the costs of research and development during the 2018 Financial Year. The refund is in respect of eligible R&D activities across Starpharma’s portfolio, including VivaGel® and DEP® programs. This amount was not included in Starpharma’s cash balance reported in the Company’s Interim Report for the half-year ended 31 December 2018.

Read More

Starpharma Interim Report and Half-Year Financial Results

Feb 27th, 2019

Melbourne, Australia: Starpharma (ASX: SPL, OTCQX: SPHRY) today released its interim report and financial results for the half-year ended 31 December 2018.

Read More

Quarterly Cashflow Report

Jan 30th, 2019

Melbourne, Australia: Starpharma (ASX: SPL, OTCQX: SPHRY) today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 December 2018

Read More

VivaGel® condom receives final regulatory approval in Japan

Jan 2nd, 2019

Melbourne, Australia; 2 January 2019: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that the VivaGel® condom has received final regulatory approval and is now able to be marketed in Japan, following the completion of the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) review of the product’s medical device classification and associated data. This final approval follows on from the previously granted regulatory certification, which was attained for the VivaGel® condom.

 

Read More

US FDA requests further data for VivaGel® BV approval

Dec 27th, 2018

Melbourne, Australia: Starpharma today received advice from the US FDA that it will require confirmatory clinical data prior to approving VivaGel® BV for treatment of bacterial vaginosis (BV) and the prevention of recurrent BV (rBV).

Read More

US VivaGel® BV licensed for A$142M milestones, plus royalties

Dec 20th, 2018

Melbourne, Australia: Starpharma and ITF Pharma today announced they have signed a licence for the sales and marketing rights to VivaGel® BV in the United States. Starpharma will be eligible to receive up to US$101M (A$142M) in regulatory approval and commercialisation milestones in addition to attractive tiered royalties on sales.

Read More

US patent granted for SPL7013 eye drops for conjunctivitis

Dec 12th, 2018

Melbourne, Australia: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that the US Patent and Trademark Office has granted a patent for SPL7013 ophthalmic drops for viral conjunctivitis. The patent has been granted with broad claims for treating and preventing microbial infections of the eye, including adenoviral conjunctivitis, bacterial conjunctivitis and other eye infections. The patent term is to 2033.

Read More

AGM - Chairman address and CEO presentation

Nov 29th, 2018

Melbourne, Australia: Attached is the Chairman’s address together with the CEO’s presentation to the Annual General Meeting of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), to be held at 3.00pm today.

Read More

DEP® docetaxel and DEP® cabazitaxel outperform in human pancreatic cancer model

Nov 16th, 2018

Melbourne, Australia: Starpharma today announced that its proprietary DEP® docetaxel and DEP® cabazitaxel products, which are both currently in the clinic, showed significant efficacy and safety benefits over gemcitabine (Gemzar®) alone, Abraxane® (Nab-paclitaxel) alone and in combination, in a human pancreatic cancer model. These impressive efficacy results were despite the fact that these standard pancreatic cancer treatments, gemcitabine and/or Abraxane® showed limited activity in this model.

Read More

Quarterly Cashflow Report

Oct 26th, 2018

Melbourne, Australia: Starpharma (ASX: SPL, OTCQX: SPHRY) today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 September 2018

Read More

Starpharma Investor Presentation for Citi Conference

Oct 17th, 2018

Melbourne, Australia: Starpharma (ASX: SPL, OTCQX: SPHRY) will today participate in Citi's 10th Annual Australian and New Zealand Investment Conference in Sydney.

Read More

DEP® irinotecan outperforms in pancreatic cancer model

Sep 5th, 2018

Melbourne, Australia: Starpharma today announced that its proprietary DEP® irinotecan development candidate showed significant efficacy and safety benefits over standard irinotecan in combination with 5-FU in a mouse xenograft model of human pancreatic cancer (Figure 1 and 2). The human pancreatic tumour model used in this study virtually did not respond to the traditional irinotecan regimen (irinotecan + 5-FU), whereas complete tumour regression and 100% survival was achieved using Starpharma’s DEP® irinotecan.

Read More

AstraZeneca’s DEP Bcl2/xL inhibitors show compelling efficacy and synergy in combination

Aug 31st, 2018

Melbourne, Australia; Starpharma today announced AstraZeneca’s first patent application on DEP® Bcl2/xL conjugates has been published by the World Intellectual Property Organisation. These DEP® Bcl2/xL conjugates combine Starpharma’s innovative DEP® delivery technology with AstraZeneca’s novel Bcl2/xL inhibitor for treating various cancers, including leukemias.

The published patent application shows compelling efficacy data on DEP® Bcl2/xL conjugates, both alone and in combination with other leading current anti-cancer treatments, in various preclinical human tumour models.

Read More

Annual report and full year financial results

Aug 21st, 2018

Melbourne, Australia: Starpharma today released its annual report and financial results for the year ended 30 June 2018.

Read More

Starpharma CEO Dr Jackie Fairley interviewed by Alan Kohler on Talking Business

Jul 1st, 2018

Starpharma CEO Dr Jackie Fairley speaks with Alan Kohler about how the company has taken VivaGel® BV from discovery to market and developed commercial products with its proprietary dendrimer technology platform.

To listen to the podcast, click here.

Read More

Starpharma CEO Jackie Fairley featured on Qantas’ inflight magazine Travel Insider

Jul 1st, 2018

Starpharma CEO Dr Jackie Fairley was featured in Qantas’ inflight magazine. To read the article, click here.

Read More

Mundipharma licenses Starpharma’s VivaGel® BV

May 3rd, 2018

Melbourne, Australia: Starpharma (ASX: SPL, OTCQX: SPHRY) and Mundipharma today announced they have signed a multi-region licence for the sales and marketing rights to VivaGel® BV in Asia (including China, Japan and Korea), the Middle East, Africa and the majority of Latin America.

Read More

Quarterly Cashflow Report

Apr 30th, 2018

Melbourne, Australia: Starpharma (ASX: SPL, OTCQX: SPHRY) today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 March 2018.

Read More

Starpharma to present at OTCQX Virtual Investor Conference

Apr 11th, 2018

Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that as part of its OTCQX investor communications, a pre-recorded presentation by Chief Executive Officer Dr Jackie Fairley will be broadcast at VirtualInvestorConferences.com on Thursday 12 April 2018 at 10:30am (US ET time).

Read More

Starpharma Interim Report and Half-Year Financial Results

Feb 26th, 2018

Starpharma today released its interim report and financial results for the half-year ended 31 December 2017.

Read More

Starpharma receives $3.7M R&D tax incentive refund

Feb 22nd, 2018

Starpharma today announced that it has received a $3.7M R&D tax incentive refund associated with FY17 expenditures. The refund relates to eligible R&D expenditure across Starpharma’s portfolio, including VivaGel® and DEP® programs.

Read More

Shareholder Update February 2018

Feb 19th, 2018

In this issue: 

>> New sites open for the DEP® docetaxel phase 2 trial

>> DEP® cabazitaxel phase 1 / 2 trial commences

>> VivaGel® BV NDA submission lodged under Fast Track program

>> VivaGel® BV approved by TGA

>> DEP® irinotecan progressing towards the clinic

>> AstraZeneca-Starpharma collaboration

>> Extensive global licensing negotiations for VivaGel® BV

>> Positive market research findings for VivaGel® BV 

>> Q2 Cashflow Report at 31 December 2017

>> OTCQX market recognition

>> Starpharma News & Events

>> Outlook

 Download: Shareholder Update February 2018 (pdf file, 1.5mb)

Read More

Starpharma announces DEP cabazitaxel Phase 1/2 Trial

Jan 31st, 2018

Morningstar reported on Starpharma's announcement regarding the commencement of its phase 1/2 clinical trial for DEP cabazitaxel having received regulatory and ethics approvals. 

Go to article (external link)

Read More

Starpharma to commence DEP® cabazitaxel phase 1/2 trial

Jan 31st, 2018

Starpharma today announced that it has received regulatory and ethics approvals to commence its phase 1/2 clinical trial for DEP® cabazitaxel. The objectives of the trial are to evaluate the safety, tolerability and pharmacokinetics of DEP® cabazitaxel, to define a recommended phase 2 dose (RP2D), and then to determine anti-tumour efficacy of the product in select tumour types.

Read More

AstraZeneca plans to make better use of Australia’s innovation

Jan 23rd, 2018

The Australian highlighted Starpharma’s partnership with global pharmaceutical company AstraZeneca, noting the application of Starpharma’s DEP® technology platform helps make cancer drugs more effective, more patient-friendly and less toxic.
Go to the article (external link)

Read More

VivaGel® BV treatment clinical submission under rolling submission

Dec 21st, 2017

Melbourne, Australia; 21 December 2017: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that it has completed the VivaGel® BV treatment clinical section of the NDA clinical module, which will be submitted to the FDA under Starpharma’s rolling submission on Friday 22 December 2017 (US time). 

Read More

VivaGel® BV granted marketing approval in Australia

Oct 25th, 2017

Starpharma today announced it has received Australian marketing approval from the Therapeutic Goods Administration (TGA) for VivaGel® BV, which is intended for treatment of bacterial vaginosis (BV).

Read More

Shareholder Update October 2017

Oct 18th, 2017

In this issue: 

>> DEP® docetaxel achieves positive phase 1 results and commences phase 2

 >> AZ presents first DEP® candidate AZD0466 – a Bcl2/xL inhibitor

>>  Successful VivaGel® BV phase 3 results

>> Update on other internal DEP® candidates

>> Grant awarded to Starpharma-Monash

>> Starpharma and Peter Mac Cancer Centre awarded grant

>> FY17 Financial results; >$60M cash at 30 June

>> Annual Report and Annual General Meeting

>> Starpharma News & Events

 

Download: Shareholder Update October 2017 (pdf file, 1.3mb)

Read More

Starpharma and Peter Mac Cancer Centre awarded DEP® Grant

Oct 9th, 2017

Starpharma and Peter MacCallum Cancer Centre have been awarded a further Federal Government Innovation Connections grant to support innovative research within Starpharma’s DEP® oncology program

Read More

AstraZeneca presents first DEP® candidate as Bcl2/xL inhibitor

Sep 28th, 2017

 Starpharma advises that AstraZeneca has this week presented its first DEP® candidate utilising Starpharma’s DEP® delivery platform,  AZD0466, at the 3rd AstraZeneca-MedImmune-CRUK Cambridge Centre Symposium 2017 in Cambridge, UK.

Read More

Starpharma rockets on cancer drug hope

Sep 23rd, 2017

The Herald Sun noted strong investor interest and support for Starpharma regarding its positive phase 1 DEP® docetaxel trial and that no neutropenia was reported in any patients.

Go to article

Read More

DEP® docetaxel positive phase 1 results; phase 2 commences

Sep 22nd, 2017

Starpharma today announced that its phase 1 trial for DEP® docetaxel has achieved the key objective of determining a Recommended Phase 2 Dose (RP2D), with no reports of protocol-defined dose limiting toxicities (DLTs). The trial has now been adapted to transition seamlessly into phase 2, with ethics and regulatory approvals already granted, and recruitment and patient screening activities underway for this next phase.

Read More

Starpharma featured on Sky Business News

Aug 28th, 2017

Starpharma CEO Dr Jackie Fairly was interviewed on Sky Business News’ Ticky following the company’s successful Phase 3 trial results for VivaGel® BV for the treatment of recurrent bacterial vaginosis. Dr Fairley discussed the commercial significance of the announcement and liaising with the US FDA to bring the product to market.

To watch the interview, click here

Read More

Starpharma annual report and full year financial results

Aug 28th, 2017

Melbourne, Australia; 28 August 2017: Starpharma (ASX: SPL, OTCQX: SPHRY) today released its annual report and financial results for the year ended 30 June 2017.


 

Read More

Starpharma CEO on Finance News Network

Aug 24th, 2017

Finance News Network featured Dr Jackie Fairley as she discussed the company’s VivaGel® BV Phase 3 results for recurrent bacterial vaginosis, the company's sale of its agrochemical business for $35M, and progress with its DEP® drug delivery programs (both internal and external).

To watch the interview, click here

Read More

Seeking Alpha covers Starpharma

Aug 11th, 2017

Online stock market insights and research publication Seeking Alpha covered Starpharma’s Phase 3 results for VivaGel® BV for the treatment of recurrent bacterial vaginosis and noted the “substantial upside” of the announcement.

To view the article, click here.

Read More

Starpharma and Monash awarded STEM+ Business fellowships

Aug 10th, 2017

Biotech news and industry publication Biotech Dispatch covered the news that Starpharma and the Monash Institute of Pharmaceutical Sciences (MIPS) were awarded $300,000 in grant funding from the SIEF STEM+ Business Fellowship Program to engage two post-doctoral Research Fellows. The funding allows both Starpharma and Monash to further advance collaborative programs utilising Starpharma’s DEP platform.

To view the article, click here.

Read More